| |   | | | | By Damian Garde and Rachel Cohrs STAT The FDA has not made clear what it's changed since the Aduhelm debacle, even as it is expected to approve another Alzheimer’s drug this week. Read More | | By Sarah Owermohle Alex Brandon/AP Officials have promised reforms in food, drug, and public health agencies and are racing to fix pandemic-exposed cracks in health care. Read More | | By Adam Feuerstein Ryan Pierse/Getty Images Drugs for Alzheimer's, psychosis, sickle cell disease, and glioma in children are expected to hit pivotal marks. Read More | | Sponsored Insight by STAT+ STAT@JPM: Join us in SF On January 9, the STAT biotech team will be in San Francisco to help you digest all the biggest stories from the year’s biggest investor conference. Join the cocktails and conversation. | | By Usha Lee McFarling Adobe Offering $100 widened disparities in study enrollment, but a $500 incentive closed the participation gap completely. Read More | | By Katie Palmer Adobe Health providers have started offering payment plans for patients through lenders like Afterpay and Affirm. Read More | | By Bob Herman and Tara Bannow Christine Kao/STAT STAT’s business reporters will be paying attention to three hospital and insurance trends next year. Read about them here. Read More | |
No comments